In this study, a 10 mg tasocitinib (CP-690,550) tablet will be administered to healthy subjects on two separate dosing occasions. On one occasion the tasocitinib (CP-690,550) tablet will be administered in a fasting condition; On the other occasion the tasocitinib (CP-690,550) tablet will be administered in a fed condition following a standard breakfast meal. The amount of tasocitinib (CP-690,550) in the blood will be measured at various times over 24 hours following each dosing occasion and compared to evaluate for any differences.
To evaluate the effect of food on the pharmacokinetics of tasocitinib (CP-690,550).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
16
Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
Pfizer Investigational Site
Singapore, Singapore
AUCinf and Cmax of tasocitinib (CP-690,550).
Time frame: PK blood samples out to 24 hours post dose in each of two periods.
AUClast, Tmax, and t1/2 of tasocitinib (CP-690,550).
Time frame: PK blood samples out to 24 hours post dose in each of two periods.
Safety: Laboratory tests.
Time frame: Pre-dose on Day O of Period 1 and post-dose on Day 2 of Period 2.
Safety:Vital signs.
Time frame: Prior to dosing in Period 1 and 2.
Safety: AE reporting.
Time frame: Continuous
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.